Obesity Drugs' Brain Effects Remain Unclear
Adults taking semaglutide or tirzepatide should know the human evidence on memory is mixed and does not yet show protection.
Updated on Nov. 6, 2026 in Alzheimer’s
Live Poll
Would you trust weight-loss drugs to help protect your memory?
Researchers from the University of Gothenburg and the University of Copenhagen published a review in Science assessing whether drugs used to treat obesity may also affect the brain. The review finds the human evidence mixed, and Novo Nordisk's EVOKE and EVOKE+ trials found semaglutide did not slow disease progression in early Alzheimer's patients.
Why it matters
Semaglutide and tirzepatide are widely prescribed for obesity and type 2 diabetes, so questions about their effect on memory carry weight for a large population. The review was written at the invitation of Science to pull together evidence that is still inconsistent, at a time when interest in whether these drugs could protect the brain is growing.
The evidence combines animal studies showing GLP-1 drugs can affect memory and learning, patient-record studies linking treatment to lower dementia risk in people with type 2 diabetes, and Novo Nordisk's EVOKE and EVOKE+ trials, which found semaglutide did not slow disease progression in early Alzheimer's patients. Patient-record studies cannot establish cause, and human findings on GLP-1 drugs and memory have been mixed.
The players
Novo Nordisk
A Danish pharmaceutical company known for its diabetes and obesity treatments, including semaglutide, and sponsor of the EVOKE and EVOKE+ Alzheimer's trials.
University of Gothenburg
A Swedish public university whose researchers co-authored the review on obesity drugs and cognition.
University of Copenhagen
A Danish public university whose senior researchers co-authored the review on obesity drugs and cognition.
The details
GLP-1 drugs mimic a gut hormone that regulates appetite and blood sugar, and receptors for this hormone are also found in the brain, which is why researchers suspect they may influence memory and learning. Animal studies have shown these effects, but results in humans have not been consistent. The EVOKE and EVOKE+ trials showed changes in several biological markers of Alzheimer's disease even though the drug did not slow clinical progression. The review's authors argue that understanding whether the effects come from better metabolism or from direct action on the brain is essential to designing new treatments.
Timeline
The review was published in Science on November 6, 2026.
Health Landscape
The Phase 3 EVOKE and EVOKE+ trials did not show slowed progression with semaglutide in early Alzheimer's, which complicates earlier hopes raised by observational data on GLP-1 drugs and dementia risk. The review's authors call for future clinical trials that track memory and cognitive abilities from the start of treatment to resolve the gap.
If you take a GLP-1 drug for obesity or type 2 diabetes, the review does not suggest changing your treatment, but it is worth raising any memory concerns with your doctor. Because human findings are mixed, these drugs should not be viewed as a proven way to protect against dementia.
The takeaway
Obesity drugs may influence the brain, but the human evidence is not yet settled, and a Phase 3 Alzheimer's trial found no slowing of disease progression. If memory is a concern, discuss it with your physician rather than assuming these medications offer protection.
Further reading
For broader context on how researchers are testing treatments, see our coverage in the Alzheimer's section.
More information
Read the Science review on obesity pharmacotherapies and cognition for the full evidence.
Live Poll
Would you trust weight-loss drugs to help protect your memory?
